John Gelinas
Psychiatry · Danbury, CTNPI 1841379534
Payments from drug & device makers
Across 979 payments — averaging $371.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$103K
- Neurocrine Biosciences, Inc.$86K
- Supernus Pharmaceuticals, Inc.$56K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$43K
- Tris Pharma Inc$26K
- Corium, LLC$25K
- plus $25K from 23 others
What the payments were for
- Consulting fees$26,1557%
- Speaking & faculty fees$288,03679%
- Travel & lodging$28,9288%
- Food & beverage$20,8166%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 288 | $103,282 |
| Neurocrine Biosciences, Inc. | 131 | $86,303 |
| Supernus Pharmaceuticals, Inc. | 109 | $55,967 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $42,986 |
| Tris Pharma Inc | 107 | $25,923 |
| Corium, LLC | 55 | $24,991 |
| Takeda Pharmaceuticals U.S.A., Inc. | 47 | $13,782 |
| Sunovion Pharmaceuticals Inc. | 30 | $3,958 |
| Idorsia Pharmaceuticals US Inc | 9 | $3,527 |
| Otsuka America Pharmaceutical, Inc. | 23 | $511 |
| Alkermes, Inc. | 25 | $499 |
| Lundbeck LLC | 21 | $460 |
| Teva Pharmaceuticals USA, Inc. | 6 | $352 |
| Ironshore Pharmaceuticals Inc. | 18 | $346 |
| Axsome Therapeutics, Inc. | 10 | $263 |
| Johnson & Johnson | 6 | $110 |
| Jazz Pharmaceuticals Inc. | 5 | $91 |
| Bausch Health US, LLC | 5 | $82 |
| Vertical Pharmaceuticals, LLC | 4 | $80 |
| Janssen Scientific Affairs, LLC | 1 | $72 |
| Eisai Inc. | 4 | $66 |
| Rhodes Pharmaceuticals L.p. | 5 | $65 |
| Collegium Pharmaceutical, Inc. | 3 | $58 |
| Harmony Biosciences LLC | 2 | $51 |
| Neos Therapeutics, LP | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Avion Pharmaceuticals | 1 | $24 |
| Almatica Pharma LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$98,671
- INGREZZA$83,917
- QELBREE$45,893
- CAPLYTA$41,702
- Quillichew ER$24,649
- Dyanavel XR$24,649
- Azstarys$24,130
- Quillivant$22,619
- VYVANSE$6,484
- TRINTELLIX$6,349
- LATUDA$3,576
- QUVIVIQ$3,479
- Quillivant XR$2,150
- REXULTI$125
- UZEDY$125
How this compares
$363,989 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $205,939 |
| VraylarCariprazine Hcl | 19 | $51,172 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $23,551 |
| RexultiBrexpiprazole | 12 | $20,134 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $19,880 |
| TrintellixVortioxetine Hydrobromide | 15 | $11,670 |
| QuviviqDaridorexant Hcl | 16 | $7,688 |
| Lisdexamfetamine Dimesylate | 25 | $5,843 |
| Eszopiclone | 21 | $3,433 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $3,262 |
| Bupropion XlBupropion Hcl | 104 | $2,342 |
| Duloxetine Hcl | 82 | $2,063 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 36 | $1,653 |
| Methylphenidate ErMethylphenidate Hcl | 14 | $1,595 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 28 | $1,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $86,303 | $205,93923 claims |
| AbbVieVraylar | $103,282 | $51,17219 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $13,782 | $31,55051 claims |
| Alkermes, Inc.Lybalvi | $499 | $23,55113 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $511 | $20,13412 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $3,527 | $7,68816 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $1,184120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Danbury
- Donald AmmermanDanbury$1.5M
- Tarique PereraDanbury$383K
- Ghazi AsaadDanbury$29K
- Joseph WilliamsDanbury$28K
- Jeffrey SatinoverDanbury$16K
- Vladimir CoricNew Haven$133.7M
- Christopher VandyckNew Haven$20.8M
- Bart SloanNorwalk$6.8M
- Adam MeccaNew Haven$5.1M
- David MatuskeyFarmington$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.